Document Detail


Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment.
MedLine Citation:
PMID:  21898709     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Prenatal serotonin reuptake inhibitor (SRI) exposure has been related to adverse newborn neurobehavioral outcomes; however, these effects have not been compared to those that may arise from prenatal exposure to maternal major depressive disorder (MDD) without SRI treatment. This study examined potential effects of MDD with and without SRI treatment on newborn neurobehavior.
METHODS: This was a prospective, naturalistic study. Women were seen at an outpatient research center twice during pregnancy (26-28 and 36-38 weeks gestational age (GA)). Psychiatric diagnoses were assessed using the Structured Clinical Interview for the DSM-IV; medication use was measured with the Timeline Follow-Back instrument. Three groups were established based upon MDD diagnosis and SRI use: Control (N = 56), MDD (N = 20), or MDD + SRI (N = 36). Infants were assessed on a single occasion within 3 weeks of birth with the NICU Network Neurobehavioral Assessment Scale. Generalized Linear Modeling was used to examine neurobehavioral outcomes by exposure group and infant age at assessment.
RESULTS: Full-term infants exposed to MDD + SRIs had a lower GA than CON or MDD-exposed infants and, controlling for GA, had lower quality of movement and more central nervous system stress signs. In contrast, MDD-exposed infants had the highest quality of movement scores while having lower attention scores than CON and MDD + SRI-exposed infants.
CONCLUSION: MDD + SRI-exposed infants seem to have a different neurobehavioral profile than MDD-exposed infants in the first 3 weeks after delivery; both groups may have different neurobehavioral profiles with increasing age from birth.
Authors:
Amy L Salisbury; Katherine L Wisner; Teri Pearlstein; Cynthia L Battle; Laura Stroud; Barry M Lester
Related Documents :
22123889 - Preterm milk oligosaccharides during the first month of lactation.
21894349 - Survival and long-term neurodevelopmental outcome of the extremely preterm infant. a sy...
21874709 - Formula and scale for body surface area estimation in high-risk infants.
21885049 - New estimates and trends regarding unsafe abortion mortality.
22194469 - Volume-targeted ventilation in infants born at or near term.
21604999 - Maternal and neonatal profile of late-preterm survivors in a poorly resourced country.
15213939 - Massive leiomyosarcoma of the testis in an infant.
4036879 - Discrepant fibrinogen values during thrombolytic therapy. comparison of aca and data-fi...
3242529 - Etiologic heterogeneity of intracranial hemorrhages in preterm newborns.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-09-02
Journal Detail:
Title:  Depression and anxiety     Volume:  28     ISSN:  1520-6394     ISO Abbreviation:  Depress Anxiety     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-14     Completed Date:  2012-04-06     Revised Date:  2014-09-19    
Medline Journal Info:
Nlm Unique ID:  9708816     Medline TA:  Depress Anxiety     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1008-19     Citation Subset:  IM    
Copyright Information:
© 2011 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Depressive Disorder, Major / complications*,  drug therapy
Female
Gestational Age
Humans
Infant Behavior / drug effects*,  psychology
Infant, Newborn
Infant, Newborn, Diseases / chemically induced*
Neuropsychological Tests
Pregnancy
Prenatal Exposure Delayed Effects / psychology*
Prospective Studies
Serotonin Uptake Inhibitors / adverse effects*
Severity of Illness Index
Young Adult
Grant Support
ID/Acronym/Agency:
K23 MH065479/MH/NIMH NIH HHS; K23 MH065479-01/MH/NIMH NIH HHS; K23MH065443/MH/NIMH NIH HHS; K23MH066402/MH/NIMH NIH HHS; K23MH65479/MH/NIMH NIH HHS; R01 MH078033/MH/NIMH NIH HHS; R01 MH078033/MH/NIMH NIH HHS; R01 MH078033-01A2/MH/NIMH NIH HHS; R01MH60335/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Serotonin Uptake Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sooner or later: age at onset of generalized anxiety disorder in older adults.
Next Document:  Treatment-resistant depression in adolescents: review and updates on clinical management.